

HalioDx Signs an Agreement with SOHIN to Make Immunoscore® Colon Assay Available in Mexico

Marseille, France, July 16, 2018 – HalioDx SAS, an immuno-oncology diagnostic company, today announced that it has signed a distribution agreement with SOHIN (Mexico). Under the agreement, SOHIN becomes exclusive distributor of Immunoscore® Colon, a unique diagnostic assay that predicts the risk of recurrence of patients with early stage colon cancer in Mexico.

Oncologists and patients in Mexico will have access to Immunoscore® Colon, an assay which combines tissue diagnostic and advanced image analysis technologies to quantify T-cells which infiltrate both the core of the colon tumor and its invasive margin. The assay guides oncologists to decide on critical therapeutic options in stage II and stage III colon cancers¹. It is the very first IVD assay of the HalioDx Immunoscore® pipeline, leveraging image analysis technology to enhance clinical utility and standardization.

“There are 6 000 new cases of Colon Cancer per year in Mexico² which represent a relevant health priority in the country. For half of these patients, treatment decisions are problematic leading to over or under treatments. Thanks to Immunoscore® Colon, relapse risk assessment will be improved for these patients,” says Vincent Fert CEO of HalioDx. He added *“We are delighted to have signed this agreement with SOHIN who has a proven record of success in the highly competitive cancer diagnostics market.”*

Juana Ramirez, CEO of SOHIN, comments: *“Our agreement with HalioDx will generate significant value for our customers. We were impressed with the Immunoscore® approach and HalioDx commitment to patient benefit with such innovation which, we believe, make a significant impact on colorectal cancer”.*

Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study³ conducted on more than 2600 patients have been published in [The Lancet journal](#). The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147⁴ study.

¹ Hermitte J Immunother Cancer 2016

² Source: World Health Organization – Cancer Country Profiles, 2014

³ Pagès et al. The Lancet 2018

⁴ Sinicrope et al. Poster presentation ASCO GI 2018



Distributed by

SOHIN
Pasión por la vida

Press release

About HalioDx

The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

Two additional assays, Halioseek® & Immunosign®, have been developed by HalioDx and provide tools to help stratifying patients for immunotherapies.

HalioDx has an experienced team of more than 130 employees, a CLIA-certified laboratory and compliant facilities to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.halioldx.com and www.immunoscore-colon.com and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

Contacts

HalioDx SAS

Vincent Fert

President and CEO

+ 33 (0)4 91 29 30 90

vincent.fert@halioldx.com

ATCG Press

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

halioldx@atcg-partners.com

Twitter: twitter.com/halioldx